Vicriviroc (BioDeep_00000802776)

   


代谢物信息卡片


Vicriviroc

化学式: C28H38F3N5O2 (533.2977)
中文名称: 维立韦罗
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC1CN(CCN1C(COC)C2=CC=C(C=C2)C(F)(F)F)C3(CCN(CC3)C(=O)C4=C(N=CN=C4C)C)C
InChI: InChI=1S/C28H38F3N5O2/c1-19-16-35(14-15-36(19)24(17-38-5)22-6-8-23(9-7-22)28(29,30)31)27(4)10-12-34(13-11-27)26(37)25-20(2)32-18-33-21(25)3/h6-9,18-19,24H,10-17H2,1-5H3/t19-,24-/m0/s1

描述信息

C254 - Anti-Infective Agent > C281 - Antiviral Agent > C1660 - Anti-HIV Agent
C308 - Immunotherapeutic Agent > C63817 - Chemokine Receptor Antagonist

同义名列表

1 个代谢物同义名

Vicriviroc



数据库引用编号

6 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表


文献列表

  • Albert Y Liu, Jingyang Zhang, Peter L Anderson, Theresa Wagner, Zhenyu Pan, Melissa Peda, Kailazarid Gomez, May Beamer, Cindy Jacobson, Julie Strizki, Charlene S Dezzutti, Jeanna M Piper. Phase 1 Pharmacokinetic Trial of 2 Intravaginal Rings Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2019 03; 68(7):1129-1135. doi: 10.1093/cid/ciy652. [PMID: 30289444]
  • Craig J Hoesley, Beatrice A Chen, Peter L Anderson, Charlene S Dezzutti, Julie Strizki, Carol Sprinkle, Faye Heard, Jose Bauermeister, Wayne Hall, Cindy Jacobson, Jennifer Berthiaume, Ashley Mayo, Holly Gundacker, Nicola Richardson-Harman, Jeanna Piper. Phase 1 Safety and Pharmacokinetics Study of MK-2048/Vicriviroc (MK-4176)/MK-2048A Intravaginal Rings. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2019 03; 68(7):1136-1143. doi: 10.1093/cid/ciy653. [PMID: 30289435]
  • Athe M N Tsibris, Zixin Hu, Roger Paredes, Kay E Leopold, Opass Putcharoen, Allison L Schure, Natalie Mazur, Eoin Coakley, Zhaohui Su, Roy M Gulick, Daniel R Kuritzkes. Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures. Journal of virology. 2012 Jun; 86(12):6416-26. doi: 10.1128/jvi.00286-12. [PMID: 22491471]
  • Shabina Rehman, Mohammad Husain, Anju Yadav, Balakuntalam S Kasinath, Ashwani Malhotra, Pravin C Singhal. HIV-1 promotes renal tubular epithelial cell protein synthesis: role of mTOR pathway. PloS one. 2012; 7(1):e30071. doi: 10.1371/journal.pone.0030071. [PMID: 22253885]
  • Reem Berro, Per Johan Klasse, Danny Lascano, Ayanna Flegler, Kirsten A Nagashima, Rogier W Sanders, Thomas P Sakmar, Thomas J Hope, John P Moore. Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors. Journal of virology. 2011 Aug; 85(16):8227-40. doi: 10.1128/jvi.00767-11. [PMID: 21680525]
  • Martin Däumer, Rolf Kaiser, Rolf Klein, Thomas Lengauer, Bernhard Thiele, Alexander Thielen. Genotypic tropism testing by massively parallel sequencing: qualitative and quantitative analysis. BMC medical informatics and decision making. 2011 May; 11(?):30. doi: 10.1186/1472-6947-11-30. [PMID: 21569501]
  • Phylinda L S Chan, Philippe Jacqmin, Marc Lavielle, Lynn McFadyen, Barry Weatherley. The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects. Journal of pharmacokinetics and pharmacodynamics. 2011 Feb; 38(1):41-61. doi: 10.1007/s10928-010-9175-z. [PMID: 21088872]
  • Linos Vandekerckhove, Chris Verhofstede, Els Demecheleer, Stephane De Wit, Eric Florence, Katrien Fransen, Michel Moutschen, Wendy Mostmans, Kabamba Kabeya, Nicola Mackie, Jean Plum, Dolores Vaira, Kurt Van Baelen, Ina Vandenbroucke, Veerle Van Eygen, Herwig Van Marck, Dirk Vogelaers, Anna Maria Geretti, Lieven J Stuyver. Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment. The Journal of antimicrobial chemotherapy. 2011 Feb; 66(2):265-72. doi: 10.1093/jac/dkq458. [PMID: 21196489]
  • Adam M Knepp, Amy Grunbeck, Sourabh Banerjee, Thomas P Sakmar, Thomas Huber. Direct measurement of thermal stability of expressed CCR5 and stabilization by small molecule ligands. Biochemistry. 2011 Feb; 50(4):502-11. doi: 10.1021/bi101059w. [PMID: 21155586]
  • Ming-Yi Shen, Yan-Jun Liu, Ming-Jaw Don, Hsien-Yueh Liu, Zeng-Weng Chen, Clément Mettling, Pierre Corbeau, Chih-Kang Chiang, Yu-Song Jang, Tzu-Hsuan Li, Paul Young, Cicero L T Chang, Yea-Lih Lin, Wen-Chin Yang. Combined phytochemistry and chemotaxis assays for identification and mechanistic analysis of anti-inflammatory phytochemicals in Fallopia japonica. PloS one. 2011; 6(11):e27480. doi: 10.1371/journal.pone.0027480. [PMID: 22087325]
  • Athe M N Tsibris, Urboshi Pal, Allison L Schure, Ronald S Veazey, Kevin J Kunstman, Timothy J Henrich, P J Klasse, Steven M Wolinsky, Daniel R Kuritzkes, John P Moore. SHIV-162P3 infection of rhesus macaques given maraviroc gel vaginally does not involve resistant viruses. PloS one. 2011; 6(12):e28047. doi: 10.1371/journal.pone.0028047. [PMID: 22164225]
  • John C Tilton, Craig B Wilen, Chukwuka A Didigu, Rohini Sinha, Jessamina E Harrison, Caroline Agrawal-Gamse, Elizabeth A Henning, Frederick D Bushman, Jeffrey N Martin, Steven G Deeks, Robert W Doms. A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5. Journal of virology. 2010 Oct; 84(20):10863-76. doi: 10.1128/jvi.01109-10. [PMID: 20702642]
  • Claudia Kasserra, Angela Sansone-Parsons, Anther Keung, Ernestina Tetteh, Mahmoud Assaf, Edward O'Mara, Thomas Marbury. Renal insufficiency has no effect on the pharmacokinetics of vicriviroc in a ritonavir-containing regimen. Clinical pharmacokinetics. 2010 Jun; 49(6):397-406. doi: 10.2165/11319470-000000000-00000. [PMID: 20481650]
  • Keith W Crawford, Chonghua Li, Anther Keung, Zhaohui Su, Michael D Hughes, Wayne Greaves, Daniel Kuritzkes, Roy Gulick, Charles Flexner. Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist Vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211). Journal of acquired immune deficiency syndromes (1999). 2010 Apr; 53(5):598-605. doi: 10.1097/qai.0b013e3181c9caac. [PMID: 20071999]
  • Gerd Fätkenheuer, Christian Hoffmann, Jihad Slim, Régine Rouzier, Anther Keung, Jing Li, Michelle Treitel, Angela Sansone-Parsons, Claudia Kasserra, Edward O'Mara, Dirk Schürmann. Short-term administration of the CCR5 antagonist vicriviroc to patients with HIV and HCV coinfection is safe and tolerable. Journal of acquired immune deficiency syndromes (1999). 2010 Jan; 53(1):78-85. doi: 10.1097/qai.0b013e3181bb28dc. [PMID: 19838130]
  • Franco Maggiolo. Efavirenz: a decade of clinical experience in the treatment of HIV. The Journal of antimicrobial chemotherapy. 2009 Nov; 64(5):910-28. doi: 10.1093/jac/dkp334. [PMID: 19767318]
  • Athe M N Tsibris, Roger Paredes, Amy Chadburn, Zhaohui Su, Timothy J Henrich, Amy Krambrink, Michael D Hughes, Judith A Aberg, Judith S Currier, Karen Tashima, Catherine Godfrey, Wayne Greaves, Charles Flexner, Paul R Skolnik, Timothy J Wilkin, Roy M Gulick, Daniel R Kuritzkes. Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2009 Mar; 48(5):642-9. doi: 10.1086/597007. [PMID: 19191652]
  • Carmen D Zorrilla, Vivian Tamayo-Agrait. Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy. HIV/AIDS (Auckland, N.Z.). 2009; 1(?):41-53. doi: 10.2147/hiv.s6326. [PMID: 22096378]
  • Cheryl A Stoddart, Geneviève Nault, Sofiya A Galkina, Karen Thibaudeau, Peter Bakis, Nathalie Bousquet-Gagnon, Martin Robitaille, Maryanne Bellomo, Véronique Paradis, Patricia Liscourt, Alexandra Lobach, Marie-Eve Rivard, Roger G Ptak, Marie K Mankowski, Dominique Bridon, Omar Quraishi. Albumin-conjugated C34 peptide HIV-1 fusion inhibitor: equipotent to C34 and T-20 in vitro with sustained activity in SCID-hu Thy/Liv mice. The Journal of biological chemistry. 2008 Dec; 283(49):34045-52. doi: 10.1074/jbc.m805536200. [PMID: 18809675]
  • J M Azevedo-Pereira, Q Santos-Costa. [Chemokine receptors and its importance in the replication cycle of human immunodeficiency virus: clinical and therapeutic implications]. Acta medica portuguesa. 2008 Sep; 21(5):497-504. doi: NULL. [PMID: 19187693]
  • X de la Tribonnière, Y Yazdanpanah, J Reynes. [CCR5 antagonists: a new class of antiretrovirals]. Medecine et maladies infectieuses. 2008 Mar; 38 Suppl 1(?):S1-6. doi: 10.1016/s0399-077x(08)70537-7. [PMID: 18455055]
  • U Fritz Bredeek, Michael J Harbour. CCR5 antagonists in the treatment of treatment-naive patients infected with CCR5 tropic HIV-1. European journal of medical research. 2007 Oct; 12(9):427-34. doi: . [PMID: 17933724]
  • Roy M Gulick, Zhaohui Su, Charles Flexner, Michael D Hughes, Paul R Skolnik, Timothy J Wilkin, Robert Gross, Amy Krambrink, Eoin Coakley, Wayne L Greaves, Andrew Zolopa, Richard Reichman, Catherine Godfrey, Martin Hirsch, Daniel R Kuritzkes. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. The Journal of infectious diseases. 2007 Jul; 196(2):304-12. doi: 10.1086/518797. [PMID: 17570119]
  • Dirk Schürmann, Gerd Fätkenheuer, Jacques Reynes, Christian Michelet, Francois Raffi, Jan van Lier, Maria Caceres, Anther Keung, Angela Sansone-Parsons, Lisa M Dunkle, Christian Hoffmann. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. AIDS (London, England). 2007 Jun; 21(10):1293-9. doi: 10.1097/qad.0b013e3280f00f9f. [PMID: 17545705]
  • Timothy J Wilkin, Zhaohui Su, Daniel R Kuritzkes, Michael Hughes, Charles Flexner, Robert Gross, Eoin Coakley, Wayne Greaves, Catherine Godfrey, Paul R Skolnik, Joseph Timpone, Benigno Rodriguez, Roy M Gulick. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2007 Feb; 44(4):591-5. doi: 10.1086/511035. [PMID: 17243065]
  • Masanori Baba. Recent advances of CCR5 antagonists. Current opinion in HIV and AIDS. 2006 Sep; 1(5):367-72. doi: 10.1097/01.coh.0000239848.13205.2a. [PMID: 19372835]
  • Mike Westby, Elna van der Ryst. CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection. Antiviral chemistry & chemotherapy. 2005; 16(6):339-54. doi: 10.1177/095632020501600601. [PMID: 16329283]